NASDAQ:INVA - Innoviva Stock Price, Forecast & News

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $0.36 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.37 by $0.01. The biotechnology company earned $65.38 million during the quarter. Innoviva had a net margin of 141.80% and a return on equity of 168.69%. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Innoviva.

News headlines about INVA stock have been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innoviva earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Innoviva.

Innoviva saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 11,200,000 shares, a decrease of 6.4% from the October 31st total of 11,960,000 shares. Based on an average daily volume of 573,700 shares, the days-to-cover ratio is currently 19.5 days. Currently, 16.5% of the company's stock are sold short. View Innoviva's Current Options Chain.

Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP) and Fate Therapeutics (FATE).

Innoviva's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (2.06%), Man Group plc (1.49%), Nomura Holdings Inc. (1.04%), Chicago Equity Partners LLC (0.46%), Millennium Management LLC (0.42%) and Assenagon Asset Management S.A. (0.37%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Nomura Holdings Inc., State Street Corp, Alberta Investment Management Corp, Chicago Equity Partners LLC, James Investment Research Inc., Dupont Capital Management Corp and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, Millennium Management LLC, Squarepoint Ops LLC, First Trust Advisors LP, Barclays PLC, SG Americas Securities LLC and Redwood Investment Management LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $13.76.

Innoviva has a market capitalization of $1.39 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva.

The official website for Innoviva is http://www.inva.com/.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]